Piliel formulation: Will begin Phase II/III trial in Europe in 100 men and 100 women, with once-daily application for four months. Discussions with the FDA for

Life Medical Sciences Inc. (CHAI), Princeton, N.J. Product: Piliel formulation, which promotes angiogenesis supporting hair follicles Indication: Alopecia androgenetica (hair loss) Status: Will begin ...